Abstract | BACKGROUND: PATIENTS AND METHODS: Serum levels of IGF-1, IGF-2, and IGF-BP3 of 22 patients with localized or metastasized Ewing sarcoma treated with six cycles of vincristine/ ifosfamide/ doxorubicin/ etoposide (VIDE) chemotherapy were recorded. Baseline levels were compared with presixth cycle levels using paired t-tests and were tested for associations with EFS and OS. Continuous variables were dichotomized according to the Contal and O'Quigley procedure. Survival analyses were performed using Cox regression analysis. RESULTS: High baseline IGF-1 and IGF-BP3 serum levels were associated with EFS (hazard ratio [HR] 0.075, 95% confidence interval [CI] 0.009-0.602 and HR 0.090, 95% CI 0.011-0.712, respectively) in univariate and multivariate analyses (HR 0.063, 95% CI 0.007-0.590 and HR 0.057, 95% CI 0.005-0.585, respectively). OS was improved, but this was not statistically significant. IGF-BP3 and IGF-2 serum levels increased during treatment with VIDE chemotherapy (P=0.055 and P=0.023, respectively). CONCLUSION:
|
Authors | Stefanie de Groot, Hans Gelderblom, Marta Fiocco, Judith Vmg Bovée, Jacobus Jm van der Hoeven, Hanno Pijl, Judith R Kroep |
Journal | OncoTargets and therapy
(Onco Targets Ther)
Vol. 10
Pg. 2963-2970
( 2017)
ISSN: 1178-6930 [Print] New Zealand |
PMID | 28652778
(Publication Type: Journal Article)
|